Patents and development of HBV and HCV clinical treatment: From 2001 to April 2005

Expert Opinion on Therapeutic Patents

Volumn 15, Issue 8, 2005, Pages 1027-1039

  Chen, Zhi ^a   Zheng, Min ^b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b NONE

Author keywords

Hepatitis B virus (HBV); Hepatitis C virus (HCV); Inhibitor; Interferon (IFN); Nucleoside analogue

Indexed keywords

1,3 OXATHIOLANE DERIVATIVE; 2 AMINO 9 [2 (HYDROXYMETHYL)CYCLOPROPYLIDENEMETHYL]PURINE DERIVATIVE; 2 AMINO 9 [2 [BIS(2,2,2 TRIFLUOROETHOXY)PHOSPHONYLMETHOXY]ETHYL] 6 (4 METHOXYPHENYLTHIO)PURINE; 4 (6 AMINO 9H PURIN 9 YL) 2 CYCLOPENTENE 1 METHANOL; ACICLOVIR; ADEFOVIR; ADEFOVIR DIPIVOXIL; ADENOVIRUS VECTOR; ALPHA INTERFERON; ALPHA2B INTERFERON; AMDOXOVIR; ANTIVIRUS AGENT; BETA INTERFERON; CLEVUDINE; ELVUCITABINE; EMTRICITABINE; ENTECAVIR; FAMCICLOVIR; GAMMA INTERFERON; GANCICLOVIR; INTERFERON; LAMIVUDINE; LOBUCAVIR; NUCLEOSIDE ANALOG; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PURINE NUCLEOSIDE DERIVATIVE; RIBAVIRIN; TELBIVUDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANEMIA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIVIRAL ACTIVITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DEPRESSION; DISEASE EXACERBATION; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENTIATION; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HEMOLYSIS; HEPATITIS B; HEPATITIS C; HUMAN; NEUTROPENIA; NONHUMAN; PATENT; PURPURA; REVIEW; UREMIA; VIRAL GENE DELIVERY SYSTEM; VIRUS MUTATION;

EID: 23844488218     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.15.8.1027     Document Type: Review

References (60)

1. PERRILLO RP: Overview of treatment of hepatitis B: key approaches and clinical challenges. Semin. Liver Dis. (2004) 24(Suppl. 1):23-29.
2. HEIJTINK RA, DE WILDE GA, KRUINING J et al.: Inhibitory efect of 9-(2-Phosphonyl- methoxyethyl) adenine (PMEA) on human and duck hepatitis B virus infection. Antiviral Res. (1993) 21(2):141-153.
3. CUNDY KC: Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin. Pharmacokinet. (1999) 36(2):127-143.
4. PETERS MG, HANN HW H, MARTIN P et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology (2004) 126(1):91-101.
5. MARCELLIN P, CHANG TT, LIM SG et al.: Adefovir dipivoxil for the treatment of hepatitis B antigenpositive chronic hepatitis B. N. Engl. J. Med. (2003) 348:808-816.
6. LIM YS, SUH DJ: Current antiviral therapy for chronic hepatitis B. J. Korean Med. Sci. (2004) 19:489-494.
7. HADZIYANNIS SJ, TASSOPOULOS NC, HEATHCOTE EJ et al.: Adefovir dipivoxil for the treatment of hepatitis B antigen-negative chronic hepatitis B. N. Engl. J. Med. (2003) 348(9):800-807.
8. ADZIYANNIS SJ, PAPATHEODORIDIS GV: Treatment of HBeAg negative chronic hepatitis B with new drugs (adefovir and others). J. Hepatol. (2003) 39(Suppl.):S172-S176.
9. DUSHEIKO G.: Adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B: a review of the major clinical studies. J. Hepatol. (2003) 39(Suppl.):S116-S123.
10. YAMANAKA G, WILSON T, INNAIMO S et al. Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus. Antimicrob. Agents Chemother. (1999) 43(1):190-193.
11. BILLICH A: Entecavir (Bristol-Myers Squibb). Curr. Opin. Investig. Drugs (2001) 2(5):617-21.
12. COLONNO RJ, GENOVESI EV, MEDINA I et al.: Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J. Infect. Dis. (2001) 184(10):1236-45.
13. TASSOPOULOS N, HADZIYANNIS S, CIANCIARA J et al.: Entecavir is effective in treating patients with chronic hepatitis B who have failed lamivudine therapy. Hepatology (2001) 34:340A.
14. BRYANT ML, BRIDGES EG, PLACIDI L et al.: Antiviral β-L-nucleosides specific for hepatitis B virus infection. Antimicrob. Agents Chemother. (2001) 45(1):229-235.
15. LE GUERHIER F, PICHOUD C, GUERRET C et al.: Characterization of the antiviral effect of 2030-dideoxy-20-30-didehydro-β-L-5-fluorocytidine in the duck hepatitis B virus infection model. Antimicrob. Agents Chemother. (2000) 44(1):111-122.
16. ZHOU XJ, LIM SG, LAI CL et al.: Phase I dose-escalation pharmacokinetics of L-deoxythymidine in patients with chronic hepatitis B virus infection. Hepatology (2001) 34:629A.
17. ZHOU XJ, LIM SG, Brown NA et al.: Importance of second phase HBV clearance and viral dynamic modeling for dose optimization of hepatitis B antiviral nucleosides. Hepatology (2001) 34:324A.
18. LAI CL, LIM SG, BROWN NA et al.: A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology (2004) 40(3):719-726.
19. BUTI M, ESTEBAN R: Entecavir, FTC, L-FMAU, LdT and others. J. Hepatol. (2003) 39(Suppl.):S139-S142.
20. CHEN SH: Comparative evaluation of L-Fd4C and related nucleoside analogs promising antiviral agents. Curr. Med. Chem. (2002) 9(9):899-91.
21. ZOULIM F, BERTHILLON P, GUERHIER FL et al.: Animal models for the study of HBV infection and the evaluation of new anti-HBV strategies. J. Gastroenterol. Hepatol. (2002) 17(Suppl.):S460-S463.
22. PAPATHEODORIDIS GV, DIMOU E, PAPADIMITROPOULOS V: Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance. Am. J. Gastroenterol. (2002) 97(7):1618-1628.
23. YUEN MF, LAI CL: Treatment of chronic hepatitis B. Lancet Infect. Dis. (2001) 1(4):232-241.
24. ONO SK, KATO N, SHIRATORI Y et al.: The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J. Clin. Invest. (2001) 107(4):449-455.
25. GISH RG, TRINH H, LEUNG N et al.: Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study. J. Hepatol. (2005) 43(1):60-66.
26. PEEK SF, COTE PJ, JACOB JR et al.: Antiviral activity of clevudine [L-FMAU (1-(2-fluoro- 5-methyl-β, larabinofuranosyl)uracil)] against woodchuck hepatitis virus replication and gene expression to chronically infected woodchucks (Marmota monax). Hepatology (2001) 33(1):254-266.
27. MARCELLIN P, MOMMEJA-MARIN H, SACKS SL et al.: A Phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. Hepatology (2004) 40(1):140-148.
28. SEIGNERES B, PICHOUD C, MARTIN P, FURMAN P, TREPO C, ZOULIM F: Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses. Hepatology (2002) 36(3):710-722.
29. PRAMOOLSINSUP C: Management of viral hepatitis B. J. Gastroenterol. Hepatol. (2002) 17(Suppl.):S125-145.
30. GUDMUNDSSON KS, WANG Z, DALUGE SM et al.: Phosphoramidate protides of carbocyclic 2′,3′-dideoxy-2′,3′-didehydro-7-deazaadenosine with potent activity against HIV and HBV. Nucleosides Nucleotides Nucleic Acids. (2004) 23(12):1929-1937.
31. MANNS MP: Current state of interferon therapy in the treatment of chronic hepatitis B. Semin. Liver Dis. (2002) 22(Suppl.1):7-13.
32. CONJEEVARAM HS, LOK AS-F: Management of chronic hepatitis B. J. Hepatol. (2003) 38:S90-S103.
33. COOKSLEY WG: Treatment with interferons (including pegylated interferons) in patients with hepatitis B. Semin. Liver Dis. (2004) 24(Suppl. 1):45-53.
34. MARCELLIN P, LAU GK, BONINO F et al.: Peg-IFN-α-2α alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. (2004) 351(12):1206-1217.
35. CHAN HL, HUI AY, WONG VW, CHIM AM, WONG ML, SUNG JJ: Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. Hepatology (2005) 41(6):1357-1364.
36. BARBARO G, ZECHINI F, PELLICEFLI AM et al.: Long-term efficacy of α-2β and lamivudine in combination compared to lamivudine monotherapy in patients with hepatitis B. An Italian multicenter randomized trial. J. Hepatol. (2001) 35(3):406-411.
37. SANTANTONIO T, NIRO GA, SINISI E et al.: Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B: a controlled pilot study. J. Hepatol. (2002) 36(6):799-804.
38. JANSSEN HLA, SENTURK H, ZEUZUM S et al.: Peginterferon α-2β and lamivudine combination therapy compared with peg-IFN- α-2β for chronic HBeAg-positive hepatitis B: a randomized controlled trial in 307 patients. Hepatology (2003) 38(Suppl.1):246A.
39. LAUER GM, WALKER BD: Hepatitis C virus infection. N. Engl. J. Med. (2001) 345(1):41-52.
40. TAN SL, PAUSE A, SHI Y, SONENBERG N: Hepatitis C therapeutics: current status and emerging strategies. Nat. Rev. Drug Discov. (2002) 1(11):867-81.
41. CHUTAPUTTI A: Adverse effects and other safety aspects of the hepatitis C antivirals. J. Gastroenterol. Hepatol. (2000) 15(Suppl.):E156-163.
42. MANNS MP, MCHUTCHISON JG, GORDON SC et al.: Peg-IFN-α-2β plus ribavirin compared with IFN-α-2β plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 358(9286):958-965.
43. TAN SL, HE YP, HUANG Y, GALE M JR: Strategies for hepatitis C therapeutic intervention: now and next. Curr. Opin. Pharmacol. (2004) 4(5):465-470.
44. LLINAS-BRUNET M, BAILEY MD, GHIRO E et al.: A systematic approach to the optimization of substrate-based inhibitors of the hepatitis C virus NS3 protease: discovery of potent and specific tripeptide inhibitors. J. Med. Chem. (2004) 47(26):6584-6594.
45. LAMARRE D, ANDERSON PC, BAILEY M et al.: An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature (2003) 426(6963):186-189.
46. BEAULIEU PL, TSANTRIZOS YS: Inhibitors of the HCV NS5B polymerase: new hope for the treatment of hepatitis C infections. Curr. Opin. Investig. Drugs (2004) 5(8):838-850.
47. SUDO K, INOUE H, SHIMIZU Y et al.: Establishment of an in vitro assay system for screening hepatitis C virus protease inhibitors using high performance liquid chromatography. Antiviral Res. (1996) 32(1):9-18.
48. SUDO K, MATSUMOTO Y, MATSUSHIMA M et al.: Novel hepatitis C virus protease inhibitors: thiazolidine derivatives. Biochem. Biophys. Res. Commun. (1997) 238(2):643-647.
49. KRUGER M, BEGER C, WELCH PJ, BARBER JR, MANNS MP, WONG-STAAL F: Involvement of proteasome α-subunit PSMA7 in hepatitis C virus internal ribosome entry site-mediated translation. Mol. Cell. Biol. (2001) 21(24):8357-8364.
50. RYU KJ, KIM JH, LEE SW. Ribozyme-mediated selective induction of new gene activity in hepatitis C virus internal ribosome entry site-expressing cells by targeted trans-splicing. Mol. Ther. (2003) 7(3):386-395.
51. RANDALL G, RICE CM: Interfering with hepatitis C virus RNA replication. Virus Res. (2004) 102(1):19-25.
52. KAPADIA SB, BRIDEAU-ANDERSEN A, CHISARI FV: Interference of hepatitis C virus RNA replication by short interfering RNAs. Proc. Natl. Acad. Sci. USA (2003) 100(4):2014-2018.
53. RANDALL G, GRAKOUI A, RICE CM: Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs. Proc. Natl. Acad. Sci. USA (2003) 100(1) 235-240.
54. SEO MY, ABRIGNANI S, HOUGHTON M, HAN JH: Small interfering RNA-mediated inhibition of hepatitis C virus replication in the human hepatoma. cell line Huh-7. J. Virol. (2003) 77(1):810-812.
55. WILSON JA, JAYASENA S, KHVOROVA A et al.: RNA interference blocks gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells. Proc. Natl. Acad. Sci. USA (2003) 100(5):2783-2788.
56. YOKOTA T, SAKAMOTO N, ENOMOTO N et al.: Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep. (2003) 4(6):602-608.
57. ZHANG J, YAMADA O, SAKAMOTO T et al. Down-regulation of viral replication by adenoviral-mediated expression of siRNA against cellular cofactors for hepatitis C virus. Virology (2004) 320(1):135-143.
58. ARRIBILLAGA L, SAROBE P, ARINA A et al.: Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus. Vaccine (2005) 23(27):3493-3499.
59. MORRISSEY DV, BLANCHARD K, SHAW L et al.: Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology (2005) 41(6):1349-1356.
60. WU HL, HUANG LR, HUANG CC et al.: RNA interference-mediated control of hepatitis B virus and emergence of resistant mutant. Gastroenterology (2005) 128(3):708-716.